Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease
| Autor: | S Reddy, M. H. Tan, R Douglas, Roger S. Rittmaster, S E York, Morris L. Givner, L Lehmann, Sonia R. Salisbury, H Zwicker, E. C. Abbott, M K Gupta, A. H. Shlossberg |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male endocrine system medicine.medical_specialty Adolescent endocrine system diseases Endocrinology Diabetes and Metabolism Graves' disease medicine.medical_treatment Clinical Biochemistry Thyrotropin Biochemistry Thyrotropin receptor Endocrinology Antithyroid Agents Internal medicine Immunopathology medicine Humans Euthyroid Child Aged Autoantibodies Chemotherapy Methimazole biology business.industry Antithyroid agent Biochemistry (medical) Thyroid Receptors Thyrotropin Middle Aged medicine.disease Graves Disease Thyroxine medicine.anatomical_structure biology.protein Female Antibody business Immunoglobulins Thyroid-Stimulating |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 81:3283-3288 |
| ISSN: | 1945-7197 0021-972X |
| DOI: | 10.1210/jcem.81.9.8784084 |
| Popis: | Medical treatment of Graves' disease involves use of antithyroid drugs with or without the addition of exogenous L-T4. There have been conflicting reports as to whether the addition of T4 reduces TSH receptor antibodies and improves remission rates more than antithyroid drugs alone. To further examine the effect of drug therapy on serum concentrations of TSH receptor antibodies. 70 patients with Graves' disease were treated with methimazole (Tapazole) alone until they were euthyroid. Then they were randomized to receive either: 1) methimazole alone in a dose sufficient to normalize TSH (0.3-5.4 mIU/L; Group 1); 2) 30 mg methimazole daily plus sufficient T4 (Synthroid) to maintain TSH in the high-normal range (2.0-5.4 mIU/L; Group 2); or 3) 30 mg methimazole daily plus sufficient T4 to suppress TSH to below 0.6 mIU/L (Group 3). The duration of treatment in all groups was 18 months. At baseline and after 6 and 18 months, TSH receptor antibodies were measured both by the ability of patients' sera to stimulate cAMP production by FRTL-5 cells (thyroid-stimulating Ig) and by the ability of patients' sera to inhibit binding of radiolabeled TSH to solubilized porcine thyroid membranes (TSH-binding, inhibiting Ig). Thyroid-stimulating Ig(TSI) and TSH-binding, inhibiting Ig(TBII) concentrations were similar among the three groups at baseline. Mean baseline TSI (expressed as the percent of normal control) for all patients combined was 306 +/- 21%. Mean baseline TBII (expressed as percent inhibition of TSH binding) was 38 +/- 2%. TSI was elevated in 85% and TBII was elevated in 75% of patients at baseline. After 18 months, TSI was elevated in 64% of patients, and TBII was elevated in 28%. Serum TSI decreased by 36 +/- 5% during the study, and there was no significant difference in the degree of reduction among the three groups (P = 0.99). Serum TBII decreased by 59 +/- 3%, and there also was no significant difference among the groups (P = 0.83). At baseline, serum TBII correlated with free T4 (r = 0.33, P < 0.01), total T3 (r = 0.55, P < 0.01), and thyroid size (r = 0.35, P < 0.01). There was no correlation between TSI and any of the baseline parameters or between TSI and TBII at any timepoint. In conclusion, we found that the addition of T4 to methimazole does not result in a greater decrease in TSH receptor antibody concentrations than treatment with methimazole alone. From these results, we would predict no difference in remission rates among these patients, but confirmation of this prediction will need to await long-term follow-up of these subjects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|